Literature DB >> 18289037

Tandem repeat peptide strategy for the design of neurotrophic factor mimetics.

Francisco Molina-Holgado1, Patrick Doherty, Gareth Williams.   

Abstract

Neurotrophic factors comprise a broad family of secreted proteins that have growth promoting, survival promoting and differentiation inducing activities. Disruption of neurotrophic factor signalling is a characteristic of many central and peripheral nervous system disorders, such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, stroke, and peripheral neuropathy and pain. It follows that treating patients with neurotrophic factors might be beneficial in a range of neurological diseases. However, the promising results seen in animal models of disease have not translated well into clinical trials due to the poor pharmacokinetics associated with the intact proteins, in particular, their short in vivo half-life, low blood brain barrier permeability, limited diffusion, and undesirable effects through multiple receptor interactions. This has been the main motivation for the design of small molecule modulators of the neurotrophic factor pathways. The review gives a brief survey of the various strategies to design mimetics that have been reported in the literature with special emphasis on the tandem repeat peptide agonist approach for BDNF/NT-4/5 and N-cadherin mimetics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18289037     DOI: 10.2174/187152708783885200

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  8 in total

1.  TrkB neurotrophic activities are blocked by α-synuclein, triggering dopaminergic cell death in Parkinson's disease.

Authors:  Seong Su Kang; Zhentao Zhang; Xia Liu; Fredric P Manfredsson; Matthew J Benskey; Xuebing Cao; Jun Xu; Yi E Sun; Keqiang Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-18       Impact factor: 11.205

2.  Olesoxime protects embryonic cortical neurons from camptothecin intoxication by a mechanism distinct from BDNF.

Authors:  Caroline Gouarné; Marc Giraudon-Paoli; Mathieu Seimandi; Clotilde Biscarrat; Gwenaëlle Tardif; Rebecca M Pruss; Thierry Bordet
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

3.  Suppression of abnormal α-synuclein expression by activation of BDNF transcription ameliorates Parkinson's disease-like pathology.

Authors:  Qianqian Cao; Shilin Luo; Wei Yao; Youge Qu; Nanbu Wang; Jian Hong; Shigeo Murayama; Zhentao Zhang; Jiaxu Chen; Kenji Hashimoto; Qi Qi; Ji-Chun Zhang
Journal:  Mol Ther Nucleic Acids       Date:  2022-06-01       Impact factor: 10.183

4.  Regulation of BDNF transcription by Nrf2 and MeCP2 ameliorates MPTP-induced neurotoxicity.

Authors:  Qianqian Cao; Qiuming Zou; Xin Zhao; Yimin Zhang; Youge Qu; Nanbu Wang; Shigeo Murayama; Qi Qi; Kenji Hashimoto; Song Lin; Ji-Chun Zhang
Journal:  Cell Death Discov       Date:  2022-05-20

5.  BBB-Permeable, Neuroprotective, and Neurotrophic Polysaccharide, Midi-GAGR.

Authors:  Vishruti Makani; Yong-Gil Jang; Kevin Christopher; Wesley Judy; Jacob Eckstein; Kenneth Hensley; Nicolas Chiaia; Dong-Shik Kim; Joshua Park
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

6.  Neurogenic and neurotrophic effects of BDNF peptides in mouse hippocampal primary neuronal cell cultures.

Authors:  Maria del Carmen Cardenas-Aguayo; Syed Faraz Kazim; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

Review 7.  7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders.

Authors:  Chaoyang Liu; Chi Bun Chan; Keqiang Ye
Journal:  Transl Neurodegener       Date:  2016-01-06       Impact factor: 8.014

8.  In vitro evidence for post-insult neuroprotective activity of an evolutionarily conserved motif against excitotoxic neuronal cell death.

Authors:  Phu V Tran
Journal:  Neuroreport       Date:  2019-02-06       Impact factor: 1.837

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.